Related Experiment Video
Updated: Jun 24, 2026
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
Immunohistochemical detection of MDR proteins in Wilms' tumour
I Hodorova1, S Rybarova, J Vecanova
1Department of Anatomy, Faculty of Medicine, Safarikiensis University, Kosice, Slovakia. ingrid.hodorova@post.sk
Objectives:
The aim of our work was to determine the expression of three MDR proteins (MDR1/Pgp, MRP1 and LRP/MVP) in 15 tissue samples of nephroblastoma (Wilms' tumour).
Background:
The majority of Wilms' tumours respond well to chemotherapy and are successfully cured, but a small subset displays resistance to therapy. The molecular mechanisms of drug resistance in this tumour type of childhood are still poorly analyzed. In our opinion, the elucidation of reasons for therapy failure in nephroblastomas is urgently needed before cure becomes a reality for children with this cancer.
Methods:
To demonstrate these proteins the enzyme indirect immunohistochemical method was used. The brown colour of the diaminobenzidine reaction product allowed us to define the distribution of stain clearly.
Conclusion:
Our immunohistochemical analysis did not demonstrate any expression of MDR1 in all cases of nephroblastoma (14 cases were after pre-operative chemotherapy, 1 case wasn't). The analysis of MRP1 and LRP expression in our set revealed 60% positivity for MRP1 and 26.7% positivity for LRP. The ability to recognize the multidrug resistance phenotype might assist in choosing specific chemotherapeutic regimens to improve prognosis and therapy (Tab. 2, Fig. 2, Ref. 20). Full Text (Free, PDF) www.bmj.sk.
Insights
Multidrug resistance proteins MRP1 and LRP/MVP were expressed in 60% and 26.7% of Wilms' tumours, respectively. MDR1/Pgp was not detected, suggesting potential therapeutic targets for childhood kidney cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pediatric Pathology
Background:
- Wilms' tumour (nephroblastoma) is a common childhood kidney cancer with generally good treatment outcomes.
- A subset of Wilms' tumours exhibits resistance to chemotherapy, necessitating further research into underlying mechanisms.
- Understanding drug resistance in pediatric cancers is crucial for improving treatment efficacy and patient survival.
Purpose of the Study:
- To investigate the expression of three key multidrug resistance (MDR) proteins: MDR1/Pgp, MRP1, and LRP/MVP.
- To analyze the presence of these proteins in 15 tissue samples of nephroblastoma.
- To correlate MDR protein expression with potential therapeutic strategies for Wilms' tumour.
Main Methods:
- Utilized indirect immunohistochemistry with diaminobenzidine for protein detection.
- Examined 15 tissue samples of nephroblastoma.
- Assessed the spatial distribution and intensity of MDR protein staining.
Main Results:
- No expression of MDR1/Pgp was detected in any of the analyzed nephroblastoma samples.
- MRP1 expression was observed in 60% of the tissue samples.
- LRP/MVP expression was found in 26.7% of the tissue samples.
Conclusions:
- MDR1/Pgp does not appear to be a significant factor in multidrug resistance in this cohort of Wilms' tumours.
- The expression of MRP1 and LRP/MVP suggests their potential involvement in chemotherapy resistance in nephroblastoma.
- Identifying MDR phenotypes could guide the selection of tailored chemotherapeutic regimens to improve patient prognosis.
